

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: DELANY et al.

Serial No.: To be assigned

Filed: Concurrently herewith

For: HUMAN VANILLOID RECEPTORS AND THEIR USES

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☐ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/EP99/09284 is submitted herewith. All of the publications cited in the International Search Report or International Preliminary Examination Report are listed on the attached form PTO-1449. (37 CFR 1.98(d)), and applicants understand that copies have been supplied to the USPTO by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$200.00).


C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge required fees to Deposit Account No. 07-1392.
- ☐ A duplicate copy of this paper is attached.

Date: June 1, 2001

Respectfully Submitted,



Frank P. Grassler
Attorney of Record, Reg. No. 31,164

GlaxoSmithKline
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
(919) 483-1007

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

Date: 6/01/01


Marilyn Eldridge

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PG3606USW	SERIAL NO. To be assigned
	APPLICANT DELANY et al.	
	FILING DATE Concurrently herewith	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page _____

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	BA	WO9937675A	29 July 1999	PCT			
	BB	EP 0943 683A	22 Sept 1999	EP			

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

CA	Caterina, M.J. et al., <i>The capsaicin receptor: a heat-activated ion channel in the pain pathway</i> , Nature 389 (6653):816-824 (1997)
CB	EMBL Database, Heidelberg, FRG Emest2 accession number AA700891 22 December 1997, Hillier, L. et al.:zj40d01.s1 Soares fetal liver spleen INFLS S1 Homo sapiens cDNA clone 452737 3', XP002135285,
CC	EMBL Database, Heidelberg, FRG Emest6 accession number AI089668, 19 August 1998, NCI/NINDS-CGAP: "qa10f06.x1 NCI_CGAP_Brn23 Homo sapiens cDNA clone IMAGE:1686371 3'", XP002135285,
CD	Biro, T. et al., <i>Recent Advances in Understanding of Vanilloid Receptors: A Therapeutic Target for Treatment of Pain and Inflammation in Skin</i> , Journal of Investigative Dermatology Symposium Proceedings, 2 (1):56-60 (1997)

Continue on page _____

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	